SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The collaboration validates Telix’s platform and de-risks its pipeline through a partnership with a top-tier biotech. Traders should monitor program progression and any opt-in/opt-out decisions on co-funding, which will impact future revenue streams and capital allocation.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.24
T+0 close · Apr 13, 2026 · via day close
Latest settled
+2.76%
T+60 · $11.55
Vs SPY
−6.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $11.24entry
  2. T+1 · 7mo ago −4.80%α −6.01% · $10.70
  3. T+5 · 7mo ago −4.54%α −7.83% · $10.73
  4. T+20 · 6mo ago −3.65%α −11.38% · $10.83
  5. T+60 · 4mo ago +2.76%α −6.16% · $11.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals announced a strategic collaboration with Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Telix will receive an upfront payment of $40 million and has the option to earn up to $2.1 billion in aggregate milestone payments plus royalties if it opts out of co-funding. The partnership combines Telix’s radiopharmaceutical expertise with Regeneron’s antibody discovery platforms.

Key Financial Metrics

Deal Value
$40.0M

Key Facts

  • Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceuticals in a 50/50 cost and profit-sharing model.
  • Telix to receive $40 million upfront from Regeneron for four initial programs.
  • If Telix opts out of co-funding for a program, it can earn up to $535 million in milestones per program, with a total potential of $2.1 billion across multiple programs, plus low double-digit royalties.
  • Collaboration includes multiple solid tumor targets using Regeneron’s VelocImmune®-derived antibodies and joint development of radio-diagnostic tools.
  • Telix retains option to co-promote certain products and will lead commercialization of diagnostic assets.

Financial Impact

$40 million upfront payment received; potential for up to $2.1 billion in milestone payments and low double-digit royalties; 50% share of profits if co-funding is pursued.

cashrevenuefuture royaltiesdilution

Risk Factors

  • Execution risk in joint development and regulatory timelines.
  • Potential disputes or misalignment with Regeneron on program priorities.
  • Uncertainty in achieving clinical and commercial milestones necessary to trigger payments.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272316

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (9h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026